These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 22172850

  • 1. Long-term outcomes of calcineurin inhibitor withdrawal for post-liver transplant renal dysfunction.
    Mackay AJ, Angus PW, Gow PJ.
    Transplant Proc; 2011 Dec; 43(10):3802-6. PubMed ID: 22172850
    [Abstract] [Full Text] [Related]

  • 2. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [Abstract] [Full Text] [Related]

  • 3. Conversion to everolimus in liver transplant patients with renal dysfunction.
    Pérez T, Segovia R, Castro L, Roblero JP, Estela R.
    Transplant Proc; 2011 Nov; 43(6):2307-10. PubMed ID: 21839260
    [Abstract] [Full Text] [Related]

  • 4. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
    Castroagudín JF, Molina E, Romero R, Otero E, Tomé S, Varo E.
    Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
    [Abstract] [Full Text] [Related]

  • 5. Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction.
    Gustafsson F, Ross HJ, Delgado MS, Bernabeo G, Delgado DH.
    J Heart Lung Transplant; 2007 Oct; 26(10):998-1003. PubMed ID: 17919619
    [Abstract] [Full Text] [Related]

  • 6. Renal function improvement after conversion to proliferation signal inhibitors during long-term follow-up in heart transplant recipients.
    Kaplinsky E, González-Costello J, Manito N, Roca J, Barbosa MJ, Nebot M, Salazar-Mendiguchia J, Berdejo J, Mañas P, Miralles A, Cequier A.
    Transplant Proc; 2012 Nov; 44(9):2564-6. PubMed ID: 23146455
    [Abstract] [Full Text] [Related]

  • 7. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
    Cotovio P, Neves M, Santos L, Macário F, Alves R, Mota A.
    Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
    [Abstract] [Full Text] [Related]

  • 8. Impact of the conversion of the immunosuppressive regimen from prograf to advagraf or to sirolimus in long-term stable liver transplant recipients: indications, safety, and outcome.
    Perrakis A, Schwarz K, Yedibela S, Croner RS, Hohenberger W, Müller V.
    Transplant Proc; 2011 Dec; 43(10):3702-7. PubMed ID: 22172830
    [Abstract] [Full Text] [Related]

  • 9. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
    Watson CJ, Gimson AE, Alexander GJ, Allison ME, Gibbs P, Smith JC, Palmer CR, Bradley JA.
    Liver Transpl; 2007 Dec; 13(12):1694-702. PubMed ID: 18044728
    [Abstract] [Full Text] [Related]

  • 10. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity.
    Kushwaha SS, Khalpey Z, Frantz RP, Rodeheffer RJ, Clavell AL, Daly RC, McGregor CG, Edwards BS.
    J Heart Lung Transplant; 2005 Dec; 24(12):2129-36. PubMed ID: 16364861
    [Abstract] [Full Text] [Related]

  • 11. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
    De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J, Rostaing L, De Carlis L, Saliba F, Nevens F.
    Liver Transpl; 2009 Oct; 15(10):1262-9. PubMed ID: 19790150
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Predictors of improvement in renal function after calcineurin inhibitor withdrawal for post-liver transplant renal dysfunction.
    Hong MKh, Angus PW, Jones RM, Vaughan RB, Gow PJ.
    Clin Transplant; 2005 Apr; 19(2):193-8. PubMed ID: 15740554
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Calcineurin inhibitor substitution with sirolimus vs. reduced-dose calcineurin inhibitor plus sirolimus is associated with improved renal dysfunction in heart transplant patients.
    Potter BJ, Giannetti N, Edwardes MD, Cecere R, Cantarovich M.
    Clin Transplant; 2007 Apr; 21(3):305-8. PubMed ID: 17488377
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Evolution of glomerular filtration rate, renal injury markers, anemia, and angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy.
    Luna E, Cerezo I, Macias R, Villa J, Martinez C, Cubero J, Martinez R, Ferreira F, García C.
    Transplant Proc; 2011 Apr; 43(6):2187-90. PubMed ID: 21839229
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.